David Blum

David Blum

Dr. David Blum is Research Director at Inserm in the “Alzheimer & Tauopathies” laboratory, a founder unit of the Jean-Pierre Aubert Research Centre (UMR-S 1172; Lille, France). His group is particularly focused on how environmental factors affect brain disorders with a particular interest towards caffeine. His current topic in this field relates to the impact of adenosine receptor modulation in neurological and neurodegenerative disorders as well as to the better understanding of molecular effects of caffeine into the brain. David has also a strong interest to translate his findings towards clinical studies, epidemiological and genetics. David graduated at Strasbourg University, France; obtained his PhD in Neurosciences at Grenoble University, France in 1999; and developed post-doctoral research experience at ULB, Brussels, Belgium. He has been recruited as senior researcher at Inserm in 2006. His main contributions includes the description of the complex role of adenosine receptors in Huntington’s disease and the first demonstration of regulatory role of A2A receptor contribution in Tauopathies (with Dr. Lopes). David authors more that 90 papers with more that 2500 citations, including top Neuroscience Journals as Lancet Neurology, Molecular Psychiatry, Journal of Neuroscience, Neurobiology of Aging or Human Molecular Genetics. David serves in several editorial boards as associate editors and as expert for most Neuroscience journals and fundings agencies in his field.

Affiliations and Expertise

UMR Inserm U1172, LabEx DISTALZ, Jean-Pierre Aubert Research Centre, Université de Lille, Faculté de Médecine, Lille, France


Editors: David Blum & Luisa Lopes Release Date: 01 Apr 2017
Print Book:
USD 127.50
USD 150.00